Early treatment with highly effective therapy could reduce long-term disability in children with MS
23 June 2026
A new international study found children with MS who started highly effective treatment before age 18 had less disability in early adulthood than those starting later.
Smoking more than doubles the risk of relapse in MOGAD
23 June 2026
New research shows that in people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), smoking is associated with relapse rates more than twice that of those who had never smoked.
Latest trial results show BTK inhibitor fenebrutinib effective in primary progressive MS
25 February 2026
New data shows fenebrutinib delays disability progression in primary progressive MS, especially preserving arm function, with a comparable safety profile to ocrelizumab.
People with MS experience pain more frequently than the general population, research reveals
23 February 2026
A new Australian study found pain is more common in people with MS than in the general population. It describes the lived experience of different types of pain and how they occur in different proportions and severity and differ by MS type, guiding towards better management.
Tolebrutinib outcomes not as hoped for progressive MS
28 January 2026
The phase 3 clinical trial of tolebrutinib did not delay disability progression in people with primary progressive MS, and it has not been approved in the USA for non-relapsing secondary progressive MS.
Promising early results for a new BTK inhibitor for progressive MS
26 November 2025
Fenebrutinib is a new treatment from the BTK inhibitor class, which aims to target immune cells throughout the body including the brain and spinal cord to treat MS.
